Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Requires the HHS Secretary, via the FDA Commissioner, to publish an interim final rule within one year amending specified 21 CFR sections to replace generic references to tests/data with references to “nonclinical tests” and to add a definition of “nonclinical test” to certain regulatory provisions. The interim final rule is made immediately effective without the agency needing to demonstrate good cause for bypassing the usual notice-and-comment delay.
Process: bypassing notice-and-comment versus need for speed
Relative to its intended legislative type, this bill is a targeted administrative directive mandating FDA to promulgate regulatory changes implementing a prior statutory amendment.
Requires the HHS Secretary, via the FDA Commissioner, to publish an interim final rule within one year amending specified 21 CFR sections to replace generic references to tests/data with references to “nonclinical tests” and to add a definition of “nonclinical test” to certain regulatory provisions.
The interim final rule is made immediately effective without the agency needing to demonstrate good cause for bypassing the usual notice-and-comment delay.
Also makes a technical renumbering of subsection (z) to subsection (aa) in FDA statute section 505.
Content is narrow, administrative, and low-cost, making enactment likely absent procedural objections or stakeholder litigation over rulemaking process.
Relative to its intended legislative type, this bill is a targeted administrative directive mandating FDA to promulgate regulatory changes implementing a prior statutory amendment. It identifies responsible actors, a deadline, and specific regulatory provisions to amend, and it includes a technical statutory renumbering.
Process: bypassing notice-and-comment versus need for speed
These are examples from the analysis, not a ranked list of the most-affected groups.
Process: bypassing notice-and-comment versus need for speed
Generally supportive of updating regulations to recognize validated nonclinical methods and reduce animal testing where appropriate.
Concerned about the expedited interim final rule process and will want safeguards ensuring scientific validation and public input.
Views the bill as a reasonable regulatory update to align CFR with statutory changes, but worries about process and implementation details.
Will favor measures ensuring scientific validation, transparency, and predictable regulatory outcomes.
Mixed to skeptical: supports regulatory modernization and reduced burdens on developers, but objects to bypassing standard rulemaking and worries about potential safety or legal uncertainty.
Seeks stronger procedural safeguards and strict validation mandates.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Content is narrow, administrative, and low-cost, making enactment likely absent procedural objections or stakeholder litigation over rulemaking process.
The bill has not accumulated any surfaced votes yet.
Process: bypassing notice-and-comment versus need for speed
Content is narrow, administrative, and low-cost, making enactment likely absent procedural objections or stakeholder litigation over rulema…
Relative to its intended legislative type, this bill is a targeted administrative directive mandating FDA to promulgate regulatory changes implementing a prior statutory amendment. It identifies responsible actors, a de…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.